Leone Peter Brian 4

4 · ARROWHEAD PHARMACEUTICALS, INC. · Filed Oct 23, 2018

Form 4

Period: 2018-10-19

VP, Strategy & Program Mgmt

Transactions

Exercise/Conversion
Common Stock
2018-10-19$2.79/sh+30,000$83,700→ 160,000 total
Exercise/Conversion
Common Stock
2018-10-19$6.15/sh+34,375$211,406→ 194,375 total
Exercise/Conversion
Common Stock
2018-10-19$7.75/sh+66,762$517,406→ 261,137 total
Exercise/Conversion
Stock Options
2018-10-19−34,375→ 155,625 total
Exercise: $6.15From: 2016-01-01Exp: 2026-01-01→ Common Stock (34,375 underlying)
Sale
Common Stock
2018-10-19$13.49/sh−131,137$1,769,038→ 130,000 total
Exercise/Conversion
Stock Options
2018-10-19−30,000→ 190,000 total
Exercise: $2.79From: 2013-07-20Exp: 2023-07-20→ Common Stock (30,000 underlying)
Exercise/Conversion
Stock Options
2018-10-19−66,762→ 88,863 total
Exercise: $7.75From: 2015-03-06Exp: 2025-03-06→ Common Stock (66,762 underlying)

Footnotes (3)

[F1]The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.10 to $13.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
[F2]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
[F3]Represents first vesting date. Option vests over four years from date of grant.

Documents

1 file